In the first half of 2024, the company?s sales declined 3.2% year over year due to the drop in its value-tier sales amid secular declines in its digital print film business and lower demand in its computed radiography (CR) equipment and services business. The decline was partially offset by growth in the company's premium-tier revenue, which increased by 4.4% . Additionally, its nondestructive testing (NDT) rose 1.5% following price increases and volume growth. We expect continued declines in Carestream?s print film revenue over the long term. We forecast low- to mid-single-digit percent declines in total annual sales in the coming years. This reflects lower than previously expected sales in China (the company's largest market), partly due to prolonged value-based purchasing
